Immunitybio vs Nuvation Bio
Immunitybio is the larger business, with $113m of revenue in fiscal 2025 against $62.9m for Nuvation Bio (1.8 times as much). Nuvation Bio grew faster (699.0% against 668.3%). Immunitybio kept more of each dollar of sales as profit: a net margin of -310.2% against -325.3%.
| Latest fiscal year | ImmunitybioIBRX, 2025 | Nuvation BioNUVB, 2025 |
|---|---|---|
| Revenue | $113m | $62.9m |
| Revenue growth | 668.3% | 699.0% |
| Net income | −$351m | −$205m |
| Operating margin | -226.0% | -338.7% |
| Net margin | -310.2% | -325.3% |
| Return on equity | — | -53.2% |
| Free cash flow | −$309m | −$181m |
| Cash | $88.3m | $164m |
| Total debt | $326m | $52.9m |
| Debt to equity | — | 17.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 691 | 298 |
| Market value | $8.69bn | $1.61bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 16 sales | 1 buys, 16 sales |